Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent kinase 9 (CDK9) inhibitor LDC526 and its clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Patricia, Dierichs, Laura, Klein-Hitpass, Ludger, Bergmann, Anke K., Möllmann, Michael, Menninger, Sascha, Habenberger, Peter, Klebl, Bert, Siveke, Jens T., Dührsen, Ulrich, Choidas, Axel, Dürig, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570784/
https://www.ncbi.nlm.nih.gov/pubmed/33117517
http://dx.doi.org/10.1177/2040620720933761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570784/
https://www.ncbi.nlm.nih.gov/pubmed/33117517
http://dx.doi.org/10.1177/2040620720933761

Ejemplares similares